Docosahexaenoic acid

About

What it is and where it shows up.

Docosahexaenoic acid (DHA) is a long-chain omega-3 polyunsaturated fatty acid (22 carbons, 6 double bonds; 22:6 n-3) found naturally in fatty fish, marine algae, and human breast milk. It is added to infant formula, dietary supplements, and functional foods to support brain, eye, and nervous system development, and to help maintain normal triglyceride levels and cardiac function.

Safety summary

The regulatory and scientific consensus.

DHA is broadly recognised as safe at typical dietary and supplemental intakes; EFSA (2012) found no safety concerns for the general population at supplemental intakes up to approximately 1 g/day of DHA alone, and up to 5 g/day combined EPA+DHA for adults did not increase the risk of bleeding, impaired glucose homeostasis, or immune dysfunction. No formal Tolerable Upper Intake Level has been established for any population group. At very high supplemental doses, theoretical concerns include effects on platelet function and blood clotting; individuals on anticoagulant therapy should exercise caution.

Regulatory landscape

What food-safety regulators have decided.

Jurisdiction	Status	Note
EFSA (European Food Safety Authority) (European Union)	Approved	EFSA NDA Panel (2012) established a safe level of 1 g/day for supplemental DHA alone for the general population; no formal UL was set. Combined EPA+DHA up to 5 g/day does not raise safety concerns for adults. DHA-rich algal oil (e.g., from Schizochytrium limacinum strain FCC-3204) is authorised as a novel food under Regulation (EU) 2015/2283. A 2026 EFSA opinion (EFSA Journal 24(1):e9858, DOI:10.2903/j.efsa.2026.9858) was commissioned by the European Commission to reassess the 1 g/day safe level based on updated systematic reviews of human intervention studies.source
FSSAI (Food Safety and Standards Authority of India) (India)	Approved	FSSAI Infant Foods Regulations (Version II, 2024) permit DHA in infant nutrition foods from algal/fungal oil sources (Crypthecodinium cohnii, Mortierella alpina, Schizochytrium sp., Ulkenia sp.) or fish oil at a maximum of 0.5% of total fatty acids, with ARA:DHA ratio ≥ 1:1. DHA content must be ≥ 0.2% of total fatty acids if a DHA claim is made. FSS (Advertising and Claims) Regulations require a minimum of 40 mg DHA per 100 g or per 100 kcal to carry a 'source of DHA' claim. No population-wide ADI or daily intake ceiling is established for general foods.source
FDA (Food and Drug Administration) (United States)	Approved	DHA-rich algal oil produced from Schizochytrium sp. holds GRAS status for use in general foods and infant formula across numerous accepted GRAS notifications (GRN 137, 553, 677, 731, 732, 844, 1128, 1185). Maximum dietary exposure from food uses is based on 21 CFR 184.1472 (menhaden oil), capped at 3.0 g/day total omega-3 (EPA+DHA) per person per day. DHA-rich oil is classified as a nutritional ingredient, not a food additive, and does not require pre-market approval under the FD&C Act.source

Who should approach with care

Whose guidance would steer them away.

Other — Individuals on anticoagulant or antiplatelet therapy should consult a physician before taking high-dose DHA supplements, as EFSA's safety assessment identified bleeding complications and platelet function as key hazard endpoints for supplemental DHA, even though EPA+DHA combined up to 5 g/day did not significantly increase spontaneous bleeding risk in clinical trials.

Shellfish Allergy — DHA products derived from fish oil may pose a risk to individuals with fish or shellfish allergies; consumers should verify the source (algal vs. fish-derived) on product labels, as algal-derived DHA is considered a fish-free alternative.

Diabetes — EFSA's 2012 and 2026 safety reviews listed glucose homeostasis as a formal hazard endpoint when assessing supplemental DHA; while no adverse effect was confirmed at reviewed doses in most studies, individuals with diabetes on pharmacological treatment are advised to monitor their glycaemic response with high-dose supplementation.

Research citations

The sources behind this verdict.

1EFSA. Scientific Opinion on the tolerable upper intake level for supplemental docosahexaenoic acid, 2026. efsa.europa.eu
2FSSAI. Food Safety and Standards (Infant Foods) Regulations – Version II (04.01.2024), 2024. fssai.gov.in
3FDA. Agency Response Letter GRAS Notice No. GRN 000844: Algal oil (55% docosahexaenoic acid) from Schizochytrium sp., 2019. fda.gov
4FDA. GRAS Notice No. GRN 000732: Docosahexaenoic acid oil produced in Schizochytrium sp., 2018. fda.gov
5EFSA. Scientific Opinion on the Tolerable Upper Intake Level of eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA) and docosapentaenoic acid (DPA), 2012. efsa.europa.eu

Independently researched5 citations